Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38963   clinical trials with a EudraCT protocol, of which   6398   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-005249-12
    Sponsor's Protocol Code Number:EFC11759
    National Competent Authority:Greece - EOF
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2014-05-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGreece - EOF
    A.2EudraCT number2011-005249-12
    A.3Full title of the trial
    A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis
    Πολυκεντρική, τυχαιοποιημένη, διπλά τυφλή, ελεγχόμενη με εικονικό φάρμακο μελέτη παράλληλων ομάδων διάρκειας δύο ετών για την αξιολόγηση της αποτελεσματικότητας, της ασφάλειας, της ανοχής και της φαρμακοκινητικής της άπαξ ημερησίως από στόματος χορηγούμενης τεριφλουνομίδης σε παιδιατρικούς ασθενείς με υποτροπιάζουσες μορφές πολλαπλής σκλήρυνσης
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosis
    Τυχαιοποιημένη, ελεγχόμενη με εικονικό φάρμακο μελέτη διάρκειας δύο ετών για την αξιολόγηση της αποτελεσματικότητας, της ασφάλειας, της ανοχής και της φαρμακοκινητικής της άπαξ ημερησίως χορηγούμενης τεριφλουνομίδης σε παιδιατρικούς ασθενείς με υποτροπιάζουσες μορφές πολλαπλής σκλήρυνσης
    A.3.2Name or abbreviated title of the trial where available
    TERIKIDS
    A.4.1Sponsor's protocol code numberEFC11759
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1124-0983
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/209/2011
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGenzyme Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGenzyme Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSanofi-aventis AEBE
    B.5.2Functional name of contact pointΒαρβάρα Μπαρούτσου
    B.5.3 Address:
    B.5.3.1Street AddressΛεωφ. Συγγρού 348, Κτίριο Α
    B.5.3.2Town/ cityΚαλλιθέα
    B.5.3.3Post code17674
    B.5.3.4CountryGreece
    B.5.4Telephone number00302109001713
    B.5.5Fax number00302109249140
    B.5.6E-mailbarbara.baroutsou@sanofi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTeriflunomide
    D.3.2Product code HMR1726
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTERIFLUNOMIDE
    D.3.9.1CAS number 108605-62-5
    D.3.9.4EV Substance CodeSUB25218
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number14
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTeriflunomide
    D.3.2Product code HMR1726
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTERIFLUNOMIDE
    D.3.9.1CAS number 108605-62-5
    D.3.9.4EV Substance CodeSUB25218
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number7
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTeriflunomide
    D.3.2Product code HMR1726
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTERIFLUNOMIDE
    D.3.9.1CAS number 108605-62-5
    D.3.9.4EV Substance CodeSUB25218
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Multiple Sclerosis
    Πολλαπλή Σκλήρυνση
    E.1.1.1Medical condition in easily understood language
    Multiple Sclerosis
    Πολλαπλή Σκλήρυνση
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level PT
    E.1.2Classification code 10028245
    E.1.2Term Multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing forms of multiple sclerosis.
    Η αξιολόγηση της επίδρασης της τεριφλουνομίδης σε σύγκριση με το εικονικό φάρμακο στη δραστηριότητα της νόσου όπως μετράται από το χρόνο έως την πρώτη κλινική υποτροπή μετά την τυχαιοποίηση σε παιδιά και εφήβους ηλικίας 10 έως 17 ετών με υποτροπιάζουσες μορφές πολλαπλής σκλήρυνσης
    E.2.2Secondary objectives of the trial
    To assess the effect of teriflunomide in comparison to placebo on disease activity/progression measured by brain MRI and on cognitive function.
    To evaluate the safety and tolerability of teriflunomide in comparison to placebo.
    To evaluate the pharmacokinetics (PK) of teriflunomide.
    Η αξιολόγηση της επίδρασης της τεριφλουνομίδης σε σύγκριση με το εικονικό φάρμακο στη δραστηριότητα/εξέλιξη της νόσου όπως εκτιμάται με MRI εγκεφάλου και εξετάσεις της γνωστικής λειτουργίας
    Η αξιολόγηση της ασφάλειας και της ανοχής της τεριφλουνομίδης σε σύγκριση με το εικονικό φάρμακο
    Η αξιολόγηση της φαρμακοκινητικής (PK) της τεριφλουνομίδης
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Patients with relapsing multiple sclerosis (MS) based on McDonald criteria of 2010 and International Pediatric Multiple Sclerosis Study Group (IPMSG) criteria for pediatric MS:
    -at least one relapse in the 12 months preceding randomization, or
    -at least 2 relapses in the 24 months preceding randomization.
    - Equal or less than 17 years of age and equal or greater than 10 years of age at randomization.
    - Signed informed consent/assent obtained from patient and patient's legal representative.
    - Ασθενείς με διάγνωση υποτροπιάζουσας ΠΣ με βάση τα κριτήρια McDonald του 2010 και τα κριτήρια της Διεθνούς Ομάδας Μελέτης Παιδιατρικής Πολλαπλής Σκλήρυνσης για την παιδιατρική ΠΣ, οι οποίοι:
    - έχουν παρουσιάσει τουλάχιστον μία υποτροπή στους 12 μήνες πριν από την τυχαιοποίηση ή
    - έχουν παρουσιάσει τουλάχιστον 2 υποτροπές στους 24 μήνες πριν από την τυχαιοποίηση,
    - Ηλικία ≤17 ετών και ≥ 10 ετών κατά την τυχαιοποίηση
    - Λήψη υπογεγραμμένης συγκατάθεσης/συναίνεσης κατόπιν ενημέρωσης από τον ασθενή ή τον νόμιμο εκπρόσωπο του ασθενούς (γονείς ή κηδεμόνες) σύμφωνα με τους τοπικούς κανονισμούς
    E.4Principal exclusion criteria
    - Expanded disability status scale (EDSS) score greater than 5.5 at screening or randomization visit.
    - Relapse within 30 days prior to randomization.
    - Treated with cladribine or mitoxantrone within 2 years preceding randomization.
    - Treated with glatiramer acetate, interferons, natalizumab, introvenous immunoglobulins or other immunosuppressant or immunomodulatory agents such as cyclophosphamide, azathioprine, cyclosporine, methotrexate, mycophenolate, dimetthyl fumrate, fingolimod less than 3 months or five half-lives prior to randomization, whichever is greater.
    - History of human immunodeficiency virus (HIV) infection.
    - Contraindication for magnetic resonance imaging (MRI).
    - Pregnant or breast-feeding females or those who plan to become pregnant during the study.
    - Female patients of child-bearing potential not using highly effective contraceptives or (double barrier) contraceptive method.
    - Βαθμολογία EDSS > 5,5 κατά τις επισκέψεις προκαταρκτικής αξιολόγησης ή τυχαιοποίησης
    - Υποτροπή εντός 30 ημερών πριν από την τυχαιοποίηση
    - Λήψη θεραπείας με κλαδριβίνη ή μιτοξαντρόνη εντός 2 ετών πριν από την τυχαιοποίηση
    - Λήψη θεραπείας με οξική γλατιραμέρη, ιντερφερόνη, ναταλιζουμάμπη, ενδοφλέβια χορηγούμενες ανοσοσφαιρίνες ή άλλους ανοσοκατασταλτικούς ή ανοσορυθμιστικούς παράγοντες όπως κυκλοφωσφαμίδη, αζαθειοπρίνη, κυκλοσπορίνη, μεθοτρεξάτη, μυκοφαινολάτη, φουμαρικό διμεθυλεστέρα, φινγκολιμόδη λιγότερο από 3 μήνες ή πέντε χρόνους ημίσειας ζωής πριν από την τυχαιοποίηση, ανάλογα με το ποιο διάστημα είναι μεγαλύτερο
    - Ιστορικό λοίμωξης από HIV
    - Αντένδειξη για MRI
    - Έγκυες ή θηλάζουσες γυναίκες ή γυναίκες που σκοπεύουν να μείνουν έγκυες κατά τη διάρκεια της μελέτης
    - Γυναίκες ασθενείς σε αναπαραγωγική ηλικία που δεν χρησιμοποιούν άκρως αποτελεσματικά αντισυλληπτικά (διπλή μέθοδος φραγμού) ή μέθοδο αντισύλληψης
    E.5 End points
    E.5.1Primary end point(s)
    Time to first clinical relapse after randomization
    Χρόνος έως την πρώτη κλινική υποτροπή μετά την τυχαιοποίηση
    E.5.1.1Timepoint(s) of evaluation of this end point
    Over 96 weeks
    Περισσότερο από 96 εβδομάδες
    E.5.2Secondary end point(s)
    1 - Proportion of relapse free patients
    2 - Number of of new/newly enlarged T2 lesions
    3 - Number of T1 Gd-enhancing T1 lesions
    4 - Change in volume of T2 lesions
    5 - Change in volume of T1 hypointense lesions
    6 - Number of new T1 hypointense lesions
    7 - Change in brain atrophy
    8 - Change in performance on symbol digit modalities test (SDMT) and Cognitive Battery Test
    9 - Overview of safety including adverse events (AEs) based on AE reporting, physical examinations, vital signs, clinical laboratories, suspected neuropathy, electrocardiography (ECG), suspected infection
    10 - Teriflunomide pharmacokinetics (PK) to allow the dose adjustment to the 14 mg adult equivalent dose for the rest of the
    study

    1.Ποσοστό ασθενών χωρίς υποτροπή
    2.Αριθμός νέων/νεοδιευρυμένων βλαβών T2
    3.Αριθμός βλαβών Τ1 που προσλαμβάνουν γαδολίνιο
    4.Μεταβολή του όγκου των βλαβών T2
    5.Μεταβολή του όγκου των βλαβών T1 χαμηλής έντασης
    6.Αριθμός νέων βλαβών T1 χαμηλής έντασης
    7.Εγκεφαλική ατροφία
    8.Έκβαση γνωστικών λειτουργιών όπως μετράται με το SDMT και τη Σειρά Δοκιμασιών Γνωστικής Λειτουργίας
    9.Παρακολούθηση ασφάλειας συμπεριλαμβανομένων των Ανεπιθύμητων Συμβάντων βασισμένα στην αναφορά των ΑΣ, φυσική εξέταση, κλινικά εργαστήρια, υποψία νευροπάθειας, ΗΚΓ, υποψία λοίμωξης.
    10.Φαρμακοκινητική (PK) της τεριφλουνομίδης που θα επιτρέψει την προσαρμογή της δόσης στην ισοδύναμη δόση για ενήλικα των 14 mg για την υπόλοιπη μελέτη
    E.5.2.1Timepoint(s) of evaluation of this end point
    1 and 9 : Over 96 weeks
    2, 3, 4, 5, 6 and 7 : At randomization, at 24, 48 and 96 weeks
    8 : At randomization, then every 24 weeks (SDMT only) and at 96 weeks
    10 : A total of 3 PK samples (blood samples) will be collected during the beginning of study, i.e., the 4-week PK run-in period (weeks 2, 3 and 4); patients entering the open label teriflunomide arm will re-do PK run-in (3 blood samples)
    1 και 9: Περισσότερο από 96 εβδομάδες
    2, 3, 4, 5, 6 και 7: Στην τυχαιοποίηση, στις 24, 48 και 96 εβδομάδες
    8: Στην τυχαιοποίηση, μετά κάθε 24 εβδομάδες (μόνο SDMT) και στις 96 εβδομάδες
    10: Συνολικά θα συλλεχθούν 3 δείγματα PK (δείγματα αίματος) κατά τη διάρκεια της προκαταρκτικής περιόδου δηλ την περίοδο PK διάρκειας 4 εβδομάδων (Εβδομάδες 2, 3 και 4).
    Οι ασθενείς που θα ενταχθούν στο ανοικτό σκέλος της τεριφλουνομίδης θα επαναλάβουν την προκαταρκτική φάση PK (3 δείγματα αίματος)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Επιλογή να περάσουν σε ανοιχτό σκέλος με τεριφλουνομίδη για ασθενείς με υποτροπή μετά τη φάση PK
    Option to go in an open label teriflunomide arm for patients having a relapse after PK run-in phase
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA21
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    China
    Israel
    Lebanon
    Russian Federation
    Turkey
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Tελευταία επίσκεψη τελευταίου ασθενούς
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days3
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 165
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 33
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 132
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    10-17 years of age for this study; patients will give assents and parents or legal guardian will give consents
    Ηλικία 10-17 ετών για αυτή τη μελέτη. Οι ασθενείς θα συναινέσουν και οι γονείς ή ο ασκών τη νόμιμη γονική επιμέλεια θα συγκαταθέσει
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 38
    F.4.2.2In the whole clinical trial 165
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Κανένα
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-07-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-06-27
    P. End of Trial
    P.End of Trial StatusOngoing
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA